APO Research
Talk to an analyst

APO RESEARCH · REPORT

9-valent Human Papillomavirus Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global 9-valent Human Papillomavirus Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025181 pages

Choose your research edition.

Industry Research9-valent Human Papillomavirus Vaccine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal 9-valent Human Papillomavirus Vaccine Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal 9-valent Human Papillomavirus Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal 9-valent Human Papillomavirus Vaccine Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal 9-valent Human Papillomavirus Vaccine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global 9-valent Human Papillomavirus Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for 9-valent Human Papillomavirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for 9-valent Human Papillomavirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for 9-valent Human Papillomavirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for 9-valent Human Papillomavirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of 9-valent Human Papillomavirus Vaccine include Zhifei Biological Products, Walvax Biotechnology, Wantai Biological Pharmacy, GSK, Beijing Health Guard Biotechnology and Merck Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global 9-valent Human Papillomavirus Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of 9-valent Human Papillomavirus Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents 9-valent Human Papillomavirus Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the 9-valent Human Papillomavirus Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

9-valent Human Papillomavirus Vaccine Segment by Company

Zhifei Biological Products

Walvax Biotechnology

Wantai Biological Pharmacy

GSK

Beijing Health Guard Biotechnology

Merck Group

9-valent Human Papillomavirus Vaccine Segment by Type

HPV11

HPV16

HPV18

HPV6

Others

9-valent Human Papillomavirus Vaccine Segment by Application

Health Center

Epidemic Prevention Station

Hospital

Others

9-valent Human Papillomavirus Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global 9-valent Human Papillomavirus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of 9-valent Human Papillomavirus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of 9-valent Human Papillomavirus Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the 9-valent Human Papillomavirus Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of 9-valent Human Papillomavirus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of 9-valent Human Papillomavirus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of 9-valent Human Papillomavirus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. 9-valent Human Papillomavirus Vaccine Industry Trends Table 2. 9-valent Human Papillomavirus Vaccine Industry Drivers Table 3. 9-valent Human Papillomavirus Vaccine Industry Opportunities and Challenges Table 4. 9-valent Human Papillomavirus Vaccine Industry Restraints Table 5. Global 9-valent Human Papillomavirus Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global 9-valent Human Papillomavirus Vaccine Sales by Manufacturers (k units) & (2021-2026) Table 8. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Manufacturers Table 9. Global 9-valent Human Papillomavirus Vaccine Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global 9-valent Human Papillomavirus Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global 9-valent Human Papillomavirus Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global 9-valent Human Papillomavirus Vaccine Manufacturers, Product Type & Application Table 13. Global 9-valent Human Papillomavirus Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global 9-valent Human Papillomavirus Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of HPV11 Table 17. Major Manufacturers of HPV16 Table 18. Major Manufacturers of HPV18 Table 19. Major Manufacturers of HPV6 Table 20. Major Manufacturers of Others Table 21. Global 9-valent Human Papillomavirus Vaccine Sales by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global 9-valent Human Papillomavirus Vaccine Sales by Type (2021-2026) & (k units) Table 23. Global 9-valent Human Papillomavirus Vaccine Sales by Type (2027-2032) & (k units) Table 24. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Type (2021-2026) Table 25. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Type (2027-2032) Table 26. Global 9-valent Human Papillomavirus Vaccine Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global 9-valent Human Papillomavirus Vaccine Revenue by Type (2021-2026) & (k units) Table 28. Global 9-valent Human Papillomavirus Vaccine Revenue by Type (2027-2032) & (k units) Table 29. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Type (2021-2026) Table 30. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Health Center Table 32. Major Manufacturers of Epidemic Prevention Station Table 33. Major Manufacturers of Hospital Table 34. Major Manufacturers of Others Table 35. Global 9-valent Human Papillomavirus Vaccine Sales by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global 9-valent Human Papillomavirus Vaccine Sales by Application (2021-2026) & (k units) Table 37. Global 9-valent Human Papillomavirus Vaccine Sales by Application (2027-2032) & (k units) Table 38. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Application (2021-2026) Table 39. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Application (2027-2032) Table 40. Global 9-valent Human Papillomavirus Vaccine Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 41. Global 9-valent Human Papillomavirus Vaccine Revenue by Application (2021-2026) & (k units) Table 42. Global 9-valent Human Papillomavirus Vaccine Revenue by Application (2027-2032) & (k units) Table 43. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Application (2021-2026) Table 44. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Application (2027-2032) Table 45. Global 9-valent Human Papillomavirus Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global 9-valent Human Papillomavirus Vaccine Sales by Region (2021-2026) & (k units) Table 47. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Region (2021-2026) Table 48. Global 9-valent Human Papillomavirus Vaccine Sales Forecasted by Region (2027-2032) & (k units) Table 49. Global 9-valent Human Papillomavirus Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 50. North America 9-valent Human Papillomavirus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. North America 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2026) & (k units) Table 52. North America 9-valent Human Papillomavirus Vaccine Sales by Country (2027-2032) & (k units) Table 53. Europe 9-valent Human Papillomavirus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Europe 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2026) & (k units) Table 55. Europe 9-valent Human Papillomavirus Vaccine Sales by Country (2027-2032) & (k units) Table 56. Asia Pacific 9-valent Human Papillomavirus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Asia Pacific 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2026) & (k units) Table 58. Asia Pacific 9-valent Human Papillomavirus Vaccine Sales by Country (2027-2032) & (k units) Table 59. South America, Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 60. South America, Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2026) & (k units) Table 61. South America, Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales by Country (2027-2032) & (k units) Table 62. Global 9-valent Human Papillomavirus Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global 9-valent Human Papillomavirus Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 64. Global 9-valent Human Papillomavirus Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 65. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Region (2021-2026) Table 66. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Region (2027-2032) Table 67. Zhifei Biological Products Company Information Table 68. Zhifei Biological Products Business Overview Table 69. Zhifei Biological Products 9-valent Human Papillomavirus Vaccine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Zhifei Biological Products 9-valent Human Papillomavirus Vaccine Product Portfolio Table 71. Zhifei Biological Products Recent Development Table 72. Walvax Biotechnology Company Information Table 73. Walvax Biotechnology Business Overview Table 74. Walvax Biotechnology 9-valent Human Papillomavirus Vaccine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Walvax Biotechnology 9-valent Human Papillomavirus Vaccine Product Portfolio Table 76. Walvax Biotechnology Recent Development Table 77. Wantai Biological Pharmacy Company Information Table 78. Wantai Biological Pharmacy Business Overview Table 79. Wantai Biological Pharmacy 9-valent Human Papillomavirus Vaccine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Wantai Biological Pharmacy 9-valent Human Papillomavirus Vaccine Product Portfolio Table 81. Wantai Biological Pharmacy Recent Development Table 82. GSK Company Information Table 83. GSK Business Overview Table 84. GSK 9-valent Human Papillomavirus Vaccine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. GSK 9-valent Human Papillomavirus Vaccine Product Portfolio Table 86. GSK Recent Development Table 87. Beijing Health Guard Biotechnology Company Information Table 88. Beijing Health Guard Biotechnology Business Overview Table 89. Beijing Health Guard Biotechnology 9-valent Human Papillomavirus Vaccine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Beijing Health Guard Biotechnology 9-valent Human Papillomavirus Vaccine Product Portfolio Table 91. Beijing Health Guard Biotechnology Recent Development Table 92. Merck Group Company Information Table 93. Merck Group Business Overview Table 94. Merck Group 9-valent Human Papillomavirus Vaccine Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Merck Group 9-valent Human Papillomavirus Vaccine Product Portfolio Table 96. Merck Group Recent Development Table 97. Key Raw Materials Table 98. Raw Materials Key Suppliers Table 99. 9-valent Human Papillomavirus Vaccine Distributors List Table 100. 9-valent Human Papillomavirus Vaccine Customers List Table 101. Research Programs/Design for This Report Table 102. Authors List of This Report Table 103. Secondary Sources Table 104. Primary Sources List of Figures Figure 1. 9-valent Human Papillomavirus Vaccine Product Image Figure 2. Global 9-valent Human Papillomavirus Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global 9-valent Human Papillomavirus Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global 9-valent Human Papillomavirus Vaccine Sales (2021-2032) & (k units) Figure 5. Global 9-valent Human Papillomavirus Vaccine Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 9-valent Human Papillomavirus Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. HPV11 Image Figure 9. HPV16 Image Figure 10. HPV18 Image Figure 11. HPV6 Image Figure 12. Others Image Figure 13. Global 9-valent Human Papillomavirus Vaccine Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global 9-valent Human Papillomavirus Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Type (2021-2032) Figure 16. Global 9-valent Human Papillomavirus Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Type (2021-2032) Figure 19. Health Center Image Figure 20. Epidemic Prevention Station Image Figure 21. Hospital Image Figure 22. Others Image Figure 23. Global 9-valent Human Papillomavirus Vaccine Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global 9-valent Human Papillomavirus Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Application (2021-2032) Figure 26. Global 9-valent Human Papillomavirus Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 27. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Application (2021-2032) Figure 29. North America 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 30. North America 9-valent Human Papillomavirus Vaccine Sales Market Share by Country (2021-2032) Figure 31. U.S. 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 32. Canada 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 33. Mexico 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe 9-valent Human Papillomavirus Vaccine Sales Market Share by Country (2021-2032) Figure 36. Germany 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 37. France 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 38. U.K. 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 39. Italy 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 40. Netherlands 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific 9-valent Human Papillomavirus Vaccine Sales Market Share by Country (2021-2032) Figure 43. China 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 44. Japan 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 45. South Korea 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 46. Southeast Asia 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 47. India 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 48. Australia 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales Market Share by Country (2021-2032) Figure 51. Brazil 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 52. South Africa 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 53. Saudi Arabia 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 54. Turkey 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 55. Argentina 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 56. UAE 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 57. Egypt 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 58. Chile 9-valent Human Papillomavirus Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 59. Global 9-valent Human Papillomavirus Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America 9-valent Human Papillomavirus Vaccine Revenue (2021-2032) & (US$ Million) Figure 62. North America 9-valent Human Papillomavirus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe 9-valent Human Papillomavirus Vaccine Revenue (2021-2032) & (US$ Million) Figure 64. Europe 9-valent Human Papillomavirus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific 9-valent Human Papillomavirus Vaccine Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific 9-valent Human Papillomavirus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa 9-valent Human Papillomavirus Vaccine Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa 9-valent Human Papillomavirus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. 9-valent Human Papillomavirus Vaccine Value Chain Figure 70. Manufacturing Cost Structure Figure 71. 9-valent Human Papillomavirus Vaccine Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • HPV11
  • HPV16
  • HPV18
  • HPV6
  • Others
Applications
  • Health Center
  • Epidemic Prevention Station
  • Hospital
  • Others
Companies covered
  • Zhifei Biological Products
  • Walvax Biotechnology
  • Wantai Biological Pharmacy
  • GSK
  • Beijing Health Guard Biotechnology
  • Merck Group

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global 9-valent Human Papillomavirus Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global 9-valent Human Papillomavirus Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global 9-valent Human Papillomavirus Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global 9-valent Human Papillomavirus Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global 9-valent Human Papillomavirus Vaccine Market Dynamics
  1. 2.1 9-valent Human Papillomavirus Vaccine Industry Trends
  2. 2.2 9-valent Human Papillomavirus Vaccine Industry Drivers
  3. 2.3 9-valent Human Papillomavirus Vaccine Industry Opportunities and Challenges
  4. 2.4 9-valent Human Papillomavirus Vaccine Industry Restraints
3 9-valent Human Papillomavirus Vaccine Market by Manufacturers
  1. 3.1 Global 9-valent Human Papillomavirus Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global 9-valent Human Papillomavirus Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global 9-valent Human Papillomavirus Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global 9-valent Human Papillomavirus Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global 9-valent Human Papillomavirus Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global 9-valent Human Papillomavirus Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global 9-valent Human Papillomavirus Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global 9-valent Human Papillomavirus Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 9-valent Human Papillomavirus Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 9-valent Human Papillomavirus Vaccine Tier 1, Tier 2, and Tier 3
4 9-valent Human Papillomavirus Vaccine Market by Type
  1. 4.1 9-valent Human Papillomavirus Vaccine Type Introduction
  2. 4.1.1 HPV11
  3. 4.1.2 HPV16
  4. 4.1.3 HPV18
  5. 4.1.4 HPV6
  6. 4.1.5 Others
  7. 4.2 Global 9-valent Human Papillomavirus Vaccine Sales by Type
  8. 4.2.1 Global 9-valent Human Papillomavirus Vaccine Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global 9-valent Human Papillomavirus Vaccine Sales by Type (2021-2032)
  10. 4.2.3 Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Type (2021-2032)
  11. 4.3 Global 9-valent Human Papillomavirus Vaccine Revenue by Type
  12. 4.3.1 Global 9-valent Human Papillomavirus Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global 9-valent Human Papillomavirus Vaccine Revenue by Type (2021-2032)
  14. 4.3.3 Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Type (2021-2032)
5 9-valent Human Papillomavirus Vaccine Market by Application
  1. 5.1 9-valent Human Papillomavirus Vaccine Application Introduction
  2. 5.1.1 Health Center
  3. 5.1.2 Epidemic Prevention Station
  4. 5.1.3 Hospital
  5. 5.1.4 Others
  6. 5.2 Global 9-valent Human Papillomavirus Vaccine Sales by Application
  7. 5.2.1 Global 9-valent Human Papillomavirus Vaccine Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global 9-valent Human Papillomavirus Vaccine Sales by Application (2021-2032)
  9. 5.2.3 Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Application (2021-2032)
  10. 5.3 Global 9-valent Human Papillomavirus Vaccine Revenue by Application
  11. 5.3.1 Global 9-valent Human Papillomavirus Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global 9-valent Human Papillomavirus Vaccine Revenue by Application (2021-2032)
  13. 5.3.3 Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Application (2021-2032)
6 Global 9-valent Human Papillomavirus Vaccine Sales by Region
  1. 6.1 Global 9-valent Human Papillomavirus Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global 9-valent Human Papillomavirus Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global 9-valent Human Papillomavirus Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global 9-valent Human Papillomavirus Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America 9-valent Human Papillomavirus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe 9-valent Human Papillomavirus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific 9-valent Human Papillomavirus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global 9-valent Human Papillomavirus Vaccine Revenue by Region
  1. 7.1 Global 9-valent Human Papillomavirus Vaccine Revenue by Region
  2. 7.1.1 Global 9-valent Human Papillomavirus Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global 9-valent Human Papillomavirus Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global 9-valent Human Papillomavirus Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America 9-valent Human Papillomavirus Vaccine Revenue (2021-2032)
  8. 7.2.2 North America 9-valent Human Papillomavirus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe 9-valent Human Papillomavirus Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe 9-valent Human Papillomavirus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific 9-valent Human Papillomavirus Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific 9-valent Human Papillomavirus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa 9-valent Human Papillomavirus Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa 9-valent Human Papillomavirus Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhifei Biological Products
  2. 8.1.1 Zhifei Biological Products Company Information
  3. 8.1.2 Zhifei Biological Products Business Overview
  4. 8.1.3 Zhifei Biological Products 9-valent Human Papillomavirus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Zhifei Biological Products 9-valent Human Papillomavirus Vaccine Product Portfolio
  6. 8.1.5 Zhifei Biological Products Recent Developments
  7. 8.2 Walvax Biotechnology
  8. 8.2.1 Walvax Biotechnology Company Information
  9. 8.2.2 Walvax Biotechnology Business Overview
  10. 8.2.3 Walvax Biotechnology 9-valent Human Papillomavirus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Walvax Biotechnology 9-valent Human Papillomavirus Vaccine Product Portfolio
  12. 8.2.5 Walvax Biotechnology Recent Developments
  13. 8.3 Wantai Biological Pharmacy
  14. 8.3.1 Wantai Biological Pharmacy Company Information
  15. 8.3.2 Wantai Biological Pharmacy Business Overview
  16. 8.3.3 Wantai Biological Pharmacy 9-valent Human Papillomavirus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Wantai Biological Pharmacy 9-valent Human Papillomavirus Vaccine Product Portfolio
  18. 8.3.5 Wantai Biological Pharmacy Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK 9-valent Human Papillomavirus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GSK 9-valent Human Papillomavirus Vaccine Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 Beijing Health Guard Biotechnology
  26. 8.5.1 Beijing Health Guard Biotechnology Company Information
  27. 8.5.2 Beijing Health Guard Biotechnology Business Overview
  28. 8.5.3 Beijing Health Guard Biotechnology 9-valent Human Papillomavirus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Beijing Health Guard Biotechnology 9-valent Human Papillomavirus Vaccine Product Portfolio
  30. 8.5.5 Beijing Health Guard Biotechnology Recent Developments
  31. 8.6 Merck Group
  32. 8.6.1 Merck Group Company Information
  33. 8.6.2 Merck Group Business Overview
  34. 8.6.3 Merck Group 9-valent Human Papillomavirus Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck Group 9-valent Human Papillomavirus Vaccine Product Portfolio
  36. 8.6.5 Merck Group Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 9-valent Human Papillomavirus Vaccine Value Chain Analysis
  2. 9.1.1 9-valent Human Papillomavirus Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 9-valent Human Papillomavirus Vaccine Production Mode & Process
  6. 9.2 9-valent Human Papillomavirus Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 9-valent Human Papillomavirus Vaccine Distributors
  9. 9.2.3 9-valent Human Papillomavirus Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst